You are here:

obinutuzumab (Gazyvaro)

Advice

following a full submission considered under the orphan process

obinutuzumab (Gazyvaro®) is not recommended for use within NHS Scotland.

Indication under review: obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.

In a phase III study, obinutuzumab decreased the risk of disease progression compared with another monoclonal antibody in a subgroup of patients with previously untreated advanced follicular lymphoma. 

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: obinutuzumab (Gazyvaro)
SMC Drug ID: 1286/18
Manufacturer: Roche
Indication: obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 15 January 2018

Back